Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Tonsillar Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Laryngeal Neoplasms 1Kidney Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

figitumumab 2motexafin gadolinium 1Temozolomide 1Radiotherapy 1Radiosurgery 1Pemetrexed 1Paclitaxel 1Erlotinib Hydrochloride 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Large Cell × motexafin gadolinium × Clear all
NCT00365183 2013-10-31

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Pharmacyclics LLC.

Phase 2 Terminated
74 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡